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Abstract: Acetyl-L-carnitine (ALC) and propionyl-L-carnitine (PLC) are two naturally occurring 
carnitine derivates formed by carnitine acetyltransferase. The beneficial cardiovascular effects 
of ALC and PLC have been extensively evaluated in animals and humans during the last 20 years. 
For instance, many clinical trials have suggested ALC and PLC as potential strategies in the 
management of peripheral arterial disease, heart and cerebral ischemia, and congestive heart 
failure. As a result, several experts have already aimed to revise the clinical evidence supporting 
the therapeutic use of ALC and PLC. On the basis of their conclusions, our aim was a critical 
review of the effectiveness of ALC and PLC in the treatment of cardiovascular diseases. Type 2 
diabetes mellitus is an independent risk factor for the development of cardiovascular disease. 
Therefore we also describe recent studies that have addressed the emerging use of ALC and PLC 
amelioration of the insulin resistant state and its related morbidities.
Keywords: propionyl-L-carnitine, acetyl-L-carnitine, L-carnitine, cardiovascular diseases, 
insulin resistance
Introduction
L-carnitine (LC) is a non-protein amino acid, which is synthesized in mammals from 
the essential amino acids lysine and methionine or obtained from dietary sources.1,2 
Acetyl-L-carnitine (ALC) and propionyl-L-carnitine (PLC) are two naturally occurring 
carnitine derivatives the formation of which is catalyzed by carnitine acetyltransferase 
(CAT), an enzyme present in mitochondria and peroxisomes and highly expressed in 
liver and heart tissues.3,4
LC is an essential cofactor of carnitine palmitoyltransferanse 1 (CPT1), allowing 
fatty acid transport into mitochondria and the incorporation of long chain fatty acids 
into the β-oxidation cycle to obtain acetyl-CoA. LC not only plays an important role 
in fatty acid metabolism, but also in glucose metabolism through its role in modulating 
the intramitochondrial acetyl-CoA/CoA ratio and the pyruvate dehydrogenase complex 
(PDH) (Figure 1).5,6
Regulation by LC of the supply of energy is especially important in heart tissue.7 
Moreover, cardiovascular diseases, such as heart failure and ischemia, are frequently 
accompanied by decreased myocardial ATP levels leading to lower mechanical 
work efficiency.8 Thus LC and its derivatives have been considered for use in meta-
bolic therapies which may help cardiomyocytes meet their absolute need for ATP, 
preserve the pulsatile cardiac function, and maintain cell and tissue viability.9–11
Another well recognized physiological role of LC is to increase the efflux of acyl and 
acetyl groups (such as the acyl-carnitines and acetyl-carnitine, respectively) out of cells 
Vascular Health and Risk Management 2011:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
170
Mingorance et al
into the plasma, reducing the accumulation of the intermediate 
products of β-oxidation.12 Accumulation of these intermediates 
has been implicated in the development of insulin resistance 
in heart and skeletal muscle and of heart failure and 
ischemia.13–16 Accordingly, exogenous administration of PLC 
and ALC may have beneficial effects in the treatment of insulin 
resistance and cardiovascular diseases, by restoring tissue 
carnitine of skeletal muscle and myocardium.
The carnitine esters, ALC and PLC, appear to possess 
significant strengths over L-carnitine itself. Briefly, ALC, 
thanks to its chemical structure, may have a preferential 
effect on the brain tissue. As for PLC, its propionyl moiety 
may replenish one of the intermediates in the citric acid cycle 
exerting an anaplerotic effect.
The potential therapeutic effects of PLC and ALC in the 
treatment of cardiovascular diseases have been evaluated 
since the mid-1980s,17,18 and over the last decade numerous 
reviews have already attempted to summarize the experi-
mental and clinical evidence supporting these beneficial 
cardiovascular effects.9,11,19–29
On the other hand, type 2 diabetes mellitus (T2DM) is 
widely accepted to be an independent risk factor for several 
cardiovascular disorders: coronary heart disease, stroke, periph-
eral arterial disease, cardiomyopathy, and congestive heart 
failure. Interestingly, the most recent data concerning the clini-
cal use of ALC and PLC suggest these LC analogs as potential 
tools in the management of insulin resistance and T2DM.
In this review, we aim to provide a critical appraisal of 
the effectiveness of ALC and PLC in the treatment of car-
diovascular diseases, and to summarize the emerging findings 
of studies examining the likely effectiveness of PLC and 
ALC in the improvement of insulin resistance.
Therapeutic effects of L-carnitine 
analogs on cardiovascular diseases
The cardiovascular effects of L-carnitine and its analogs have 
already been extensively reviewed by various experts in this 
field. For that reason, the main aim of this section is to identify 
points in common between the different reviews rather than 
summarizing once again data from the original clinical trials.
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Figure 1 L-carnitine and energy metabolism.
Abbreviations: CPT, carnitine polmitoyl transferase; CRAT, Acetyl-carnitine transferase; CACT, carnitine-acylcarnitine translocase; TCA, tricarboxylic acid.
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Peripheral arterial disease
Peripheral arterial disease (PAD) is a clinical manifestation 
of underlying aorto-iliac and leg atherosclerosis, which is 
characterized by different degrees of stenosis and obstruc-
tion. Intermittent claudication (IC) is the main symptom 
of PAD and it is defined as cramping leg pain (in the but-
tocks, thighs, and/or calves) while/after climbing 1 or 2 
flights of stairs, or during walking.
The beneficial effects of PLC on PAD, especially in 
alleviating the IC, have been widely studied, being more 
relevant than those exerted by LC itself.30 In contrast, the 
effects of ALC on PAD have been poorly evaluated. 
Some reviews focused on these effects are the main sources 
considered in the present analysis.26,27,29
Intermittent claudication is a symptom that profoundly 
limits the patient’s ability to walk and as a result is associated 
with reduced exercise performance. Thus the primary goal 
of claudication therapy is to relieve the symptoms during 
walking and improve exercise performance and community 
activities.31 In relation to the efficacy of PLC in the treatment 
of PAD, the authors of these three reviews agreed on high-
lighting the ability of PLC to improve exercise tolerance in 
terms of increasing the maximum walking distance (MWD) 
in patients suffering from IC. This increased MWD has been 
shown to be independent of the dosage (1–3 g/day), route of 
administration (intravenous infusion or oral intake), and 
duration of PLC treatment (short or long term administration) 
used in the different studies included in the reviews 
(Table 1).30,32–41
The authors of these reviews emphasized the importance 
of the clinical trial managed by Brevetti et al33 as the largest 
study so far, recruiting 485 patients. In this pivotal trial, 
after 12 months of treatment with 2 g/day of PLC, patients 
with an initial MWD , 250 m, and randomly allocated to 
placebo, increased their MWD by 44% vs 61% in the cases 
receiving the drug (P , 0.055). However, patients with mild 
functional impairment (MWD . 250 m) showed no 
response to PLC.33
The reviewers also concluded that PLC seems to be 
able to improve most measures of quality of life (overall 
physical activity, pain while walking, and psychological 
activity) with PLC-treated patients with PAD obtaining 
better scores than placebo recipients on several different 
validated questionnaires (namely, the McMaster Health 
Index Questionnaire [MHIQ], Walking Impairment Ques-
tionnaire and the Medical Outcome Study SF-36 Question-
naire). In all the reviews, however, 1 study, focused mainly 
on assessing the effect of PLC treatment on patient quality 
of life, was noted as having failed to detect any significant 
Table 1 Main clinical trials on patients with intermittent claudication (iC) showed an increase of the maximal walking distance (MwD) 
after receiving PLC treatment, regardless of the dose, route of administration or duration used in the different studies
Patients  
(n)
PLC  
dose
Duration  
(days)
Route of  
administration
Diagnosis MWD increase P value Quality 
of life  
test
PLC Placebo
Brevetti  
et al30
33 600 mg/day 4 days i.v PAD and iC (Fontaine ii) 20 NR P , 0.01a NR
Coto  
et al32
282 2 g/day 180 Oral PAD and iC 93 35 NR NR
Brevetti  
et al33,34
214 500 mg- 
3 g/day
182 Oral iC (30 , MwD , 400)  
Severe iC (30 , MwD , 250)
157  
124
139,571 0.026b  
0.009b
√  
√
Brevetti  
et al35
485 2 g/day 365 Oral iC (50 , MwD , 400)  
Severe iC (30 , MwD , 250)
54%  
87%
48%  
46%
NSb  
P , 0.01b
X  
√
Dal Lago  
et al36
19 3 g/day 90 Oral Obliterative PAD  
(Fontaine ii)
143.3 17.7 P , 0.05b NR
Hiatt37 155 2 g/day 180 Oral PAD and iC 161 seg 75 seg P , 0.0001b √
Barker  
et al38
7 2 g/day 28 Oral PAD and iC 80 seg 0 seg NS NR
Ragozzino  
et al39
24 1, 2 g/day 10 i.v Diabetic angiopathy  
(Fontaine iib)
30% NR P , 0.05a NR
Andreozzi  
et al40
42 600 mg/day 42 i.v Moderate iC (MwD , 200)  
Severe iC (MwD , 100)
≅78.75 
≅107.37
≅60.09 
≅76.64
P , 0.006b 
P , 0.0003b
NR
Allegra  
et al41
26 900 mg/day 33 i.v Angiopathy  
(Fontaine iia and b)
157 NR P , 0.001a NR
Notes: aPlacebo period in the same group; bPlacebo group.
Abbreviations: NR, not registered; NS, not statistically significant.
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improvements in MHIQ scores in patients with mild clau-
dication treated with PLC.33
One of the symptoms leading to the development of IC 
is a decreased blood flow in patients with PAD. Wiseman 
and Brogden concluded that PLC had no direct vasoactive 
effects in patients with IC.29 However, other scholars men-
tioned the capacity of PLC to improve endothelial 
function,26,42 and some years later, Andreozzi gathered 
clinical evidence demonstrating the beneficial effects of 
PLC treatment on the vasculature of patients with PAD.27 
More precisely, this recent review concluded that PLC has 
an ability to enhance flow mediated dilatation (FMD) in 
the brachial artery,43 even when impaired post-exercise.44 
This vasoactive effect of PLC may help to prevent the 
occurrence of ischemic events in patients with PAD.
Eventually, PAD progresses from IC to ischemic ulcers 
or gangrene. In this regard, it has been mentioned in some 
reviews;27,29 many scholars have noted the importance of 
early studies demonstrating that PLC improved healing of 
ulcerative trophic lesions in patients with severe chronic 
obstructive arterial disease.29,45,46
Because patients with claudication are physically 
impaired, the treatment goals are to relieve symptoms, and 
improve exercise performance and daily quality of life.31 
Consequently, PLC should be considered not only as a 
potential or emerging candidate, but as a therapeutic 
approach that is likely to be effective for the treatment of IC 
in patients with PAD.
Its effectiveness may be enhanced by combining PLC 
with other strategies, such as exercise training, pulsed 
muscular compression therapy, or pharmacological treat-
ment with PGE-1.47,48 Accordingly, the latest update of the 
Inter-Society Consensus for the Management of PAD 
guidelines (TASC II) included the use of PLC in combina-
tion with physical training to improve the symptoms 
associated with PAD.31 We should also note that, surpris-
ingly, it has recently been reported that the long-term 
administration of PLC to patients with IC did not result 
in a statistically significant improvement in peak treadmill 
performance or quality of life compared with exercise 
alone.49
ischemic heart disease
A low carnitine concentration in the heart was observed 
in patients who died of myocardial infarction,50 so that 
PLC and ALC may be beneficial in the treatment or in the 
prevention of damage to the heart after an ischemic insult. 
In relation to this, the usefulness of LC derivatives in the 
pharmacological management of the ischemic heart has 
been strongly supported by research findings in the case 
of PLC, whereas there is only weak evidence of the effects 
of ALC on the hypoxic myocardium from isolated rat heart 
models.51–54
The role of PLC in the human pharmacology of the 
 ischemic heart has already been revised by Arsenian,19 and 
Lango et al.24 The former and more recent remarked on 
2 studies in which PLC demonstrated its beneficial effects 
in a group of 31 patients with left coronary artery disease 
treated with a single dose of 15 mg/kg of PLC and in a group 
of 18 men with stable exertional angina treated with PLC 
1.5 mg/day for 30 days, mainly in terms of a reduction in the 
ST segment depression that is normally observed after an 
ischemic episode.19,55,56 This reviewer concluded that the 
function of LC and PLC in ischemic heart disease, though 
promising, was largely speculative, however. Further, Lango 
et al in their revision only cited a study where PLC used in 
doses of 15 mg/kg caused a slight decrease in peripheral 
resistance in patients with stable coronary disease.24,57
Additional to that found in these reviews, a double-
blind, placebo-controlled study carried out with PLC on 
patients with stable angina showed a reduction of ST seg-
ment depression, together with increased total work capac-
ity and prolonged exercise duration and time to ischemic 
threshold.58 However, the anti-ischemic effects of PLC 
were less pronounced than those produced by the calcium 
antagonist diltiazem, PLC being able to reduce ST depres-
sion at maximal exercise, but not to increase the time to 
onset of angina.59
In accordance with the previous reviewers, we should 
conclude that PLC has interesting protective effects against 
myocardial ischemia, but that its role in the treatment of this 
condition is not well established.
Nevertheless, it must be pointed out that intravenous 
PLC administration prior to coronary artery bypass grafting 
significantly improved early postoperative recovery in 
diabetic patients by increasing the cardiac index and reduc-
ing pulmonary artery pressure,60 suggesting that PLC may 
be more effective in preventing ischemic injury, than in 
treatment of the consequences after an ischemic episode 
has occurred.
Cerebral ischemia
In contrast to the case of the ischemic heart, the therapeutic 
effect of ALC on cerebral ischemia has been thoroughly 
investigated, whereas we are aware of only 1 study of PLC 
administration, in a rat model of forebrain ischemia.61 
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Nevertheless, the positive results observed in this study open 
up new perspectives for the use of PLC in the treatment of 
neurodegenerative diseases associated with, or secondary to, 
myocardial ischemia-reperfusion injury and chronic circula-
tory failure.
Most of the studies focused on the evaluation of the 
effects of ALC treatment in cerebral ischemic injury did not 
describe clinical but rather experimental data, which have 
been review by different experts.22,62,63 These reviews noted 
that ALC has been reported to improve neurological 
outcome,22 prevent free radical-mediated protein oxidation,64 
normalize levels of brain energy metabolites, and decrease 
lactic acid concentration during early post-ischemia reper-
fusion.65 More recently, these findings have been confirmed 
by Jalal et al who found that pretreatment with ALC 
(400 mg/kg/day for 5 days) significantly reduced infarct size 
in focal cerebral ischemia induced using 4 models of middle 
cerebral artery occlusion in rats.66
To date, however, there are insufficient clinical data sup-
porting the use of ALC in damage prevention or treatment 
of patients with cerebral ischemia. For instance, in a very 
recent article focused on ALC,11 only 1 study performed in 
humans with brain ischemia was mentioned and that had 
been published back in 1990.67 In this study, they investigated 
the effects of ALC on regional cerebral blood flow in 10 male 
patients with brain ischemia and observed beneficial effects 
in 8 out of 10 patients 1 hour after IV administration of 
1500 mg of ALC.67
Considering the great extent of experimental data in the 
literature that strongly support the beneficial effects of ALC 
in cerebral ischemia, we note that there is a pressing need 
for well planned clinical trials considering ALC as a potential 
pharmacological instrument in patients with brain 
ischemia.
Congestive heart failure
Since PLC and ALC may improve the impaired metabolism 
of heart muscle, these LC analogs may provide considerable 
benefits as adjuncts to standard therapy in congestive heart 
failure (CHF).
Similar to the effects observed in the cardiovascular condi-
tions described above, the effectiveness of PLC in the clinical 
management of CHF has been more widely discussed than the 
use of ALC. Indeed, the effects of ALC on heart failure are 
only indirectly suggested by 2 studies, one performed in 
patients with heart failure secondary to circulatory shock and 
the other in patients with coronary artery disease, which is one 
of the main causes for development of CHF.68,69 In the former, 
115 patients with circulatory and septic shock received ALC 
infusion for 12 hours with a previous single bolus intrave-
nously. The results showed a good response to the drug in 
terms of blood oxygenation during the course of sepsis and 
heart failure.68 In the latter, 36 subjects with stable coronary 
artery disease received 500 mg oral ALC and 200 mg oral 
α-lipoic acid twice daily and their effect on vascular function 
and blood pressure were assessed. The trial consisted of two 
8-week treatment periods separated by a 4-week washout 
period, after which subjects were crossed over to the other 
group. The combined treatment increased brachial artery 
diameter by 2% to 3% and decreased systolic blood pressure 
by an average of 9 mm Hg, compared with placebo.69
The ability of PLC treatment to improve CHF was 
reviewed by Ferrari et al in 1997 and 2004.9,70 The authors 
concluded that both acute and chronic administration of PLC 
improved exercise capacity in patients with moderate and 
severe CHF (New York Heart Association classes II-IV), 
occurring in the absence of major hemodynamic and neu-
roendocrine changes, but were associated with an improved 
skeletal muscle metabolism, and were likely to decrease 
levels of the tumor necrosis factor-α, a proinflammatory 
soluble receptor that is elevated in CHF.71,72
Comparing the two reviews, only slight progress seems 
to have been made over the 7 years that elapsed between 
them in the clinical evidence supporting the use of PLC in 
CHF. Moreover, Ferrari et al also remarked on the impor-
tance of a multicenter and international study in which only 
a slight non-significant difference on exercise test duration 
was detected.73 That study found that only in a subgroup of 
patients, with an ejection fraction of 30% to 40% and with 
relatively well preserved myocardial function, were results 
in the exercise duration test enhanced significantly after PLC 
treatment.
Consequently, we can conclude that the clinical effective-
ness of PLC in the treatment of CHF is not well established.
L-carnitine analogs in diabetes 
mellitus in clinical practice
Patients with type 1 or type 2 diabetes are at high risk of vari-
ous cardiovascular disorders: coronary heart disease, stroke, 
peripheral arterial disease, cardiomyopathy, and congestive 
heart failure. Indeed, cardiovascular complications have been 
identified as the leading causes of diabetes-related morbidity 
and mortality.74
Accumulation of fatty acids and lipid metabolites (such 
as long chain acyl CoA, diacylglycerol, triacylglycerol, 
and/or ceramide) has been reported to alter the insulin action 
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pathway and consequently can be considered as a likely 
mechanism for the development of insulin resistance in heart 
and skeletal muscles, probably through the activation of 
proinflammatory pathways.75,76 LC plays an important role 
in the efflux of these intermediates from the cell and may 
also be decreasing their accumulation by inhibiting the 
transport of long chain free fatty acids into the cell. In fact, 
a connection between LC and CPT1 inhibition through an 
increase of the malonyl-CoA levels has been suggested.77 
For these reasons, LC and its derivatives may act in various 
ways to improve insulin resistance.
LC improved insulin-mediated glucose disposal has been 
demonstrated in both healthy subjects and in patients with 
T2DM.78 Since either LC or its derivatives play an important 
role in fatty acid and glucose oxidation, and both have been 
found to be altered in T2DM, it can reasonably be hypoth-
esized that PLC and ALC would have beneficial effects in 
T2DM.
For instance, the first report showing the anti-diabetic 
effect of ALC was published by Giancaterini et al 10 years 
ago.79 On different days, 18 T2DM patients received both a 
primed-constant infusion of ALC (5 mg/kg body weight 
priming bolus and either 0.025, 0.1, or 1.0 mg/kg body 
weight/min constant infusion) and a comparable placebo 
formulation. Tissue glucose uptake was signif icantly 
increased by the administration of ALC, in a dose-dependent 
manner, and was related to increased glucose storage rather 
than increased glucose oxidation.79
More recently, new data continue to point to the likely 
effectiveness of ALC administration in the clinical manage-
ment of T2DM. Bloomer et al conducted a double-blind 
clinical trial in which pre-diabetic men and women (with 
fasting blood glucose: 100–125 mg/dL) were randomly 
assigned either 3 g/day of ALC or placebo for 8 weeks, 
resulting in slight improvements in fasting glucose, HbA
1c
 
and HOMA-IR after ALC treatment.80 Further, when ALC 
was administered chronically for 24 weeks to 36 non-diabetic 
patients (2 g/day) with insulin resistance and hypertension 
at increased risk of cardiovascular disease, the treatment 
resulted in an increased glucose disposal rate and improved 
glucose tolerance in PLC-treated patients. Additionally, 
higher values of glucose disposal rate were accompanied by 
higher decreases of systolic blood pressure.81 The results of 
this pilot study may provide the basis on which to set up 
randomized, double-blind clinical trials to formally test the 
effects of ALC compared with placebo on blood pressure 
and metabolic profile in T2DM and hypertensive patients.
Finally, it should be mentioned that the effects of PLC 
on insulin resistance have been reported for the first time 
following a recent study performed in an animal model of 
obesity and insulin resistance, the fatty Zucker rat.82 Chronic 
administration of oral PLC decreased the body-weight gain, 
food intake, adiposity, insulin serum concentration, 
HOMA-IR index, and TAG liver content, demonstrating the 
considerable improvement of the insulin resistance that had 
occurred in animals receiving PLC.82
Conclusion
Although several clinical trials suggest PLC and ALC as poten-
tial pharmacological tools targeting cardiovascular pathologies 
(namely PAD, brain and heart ischemia, and CHF), only the 
effectiveness of PLC in the management of the IC in the PAD 
can be remarked. In relation to this, PLC seems to be more 
effective when it is combined with other strategies, such as 
exercise training, pulsed muscular compressions or other phar-
macological strategies, suggesting a special role of PLC as a 
coadjuvant tool in the therapy of IC. In contrast, most of the 
recent studies evaluated the efficacy of ALC in the amelioration 
of the insulin resistance state. Nevertheless, well designed and 
larger clinical trials are still necessary to establish more strongly 
the beneficial effects of the LC analogs in T2DM.
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